Bonebridge active transcutaneous bone conduction hearing implant: Results in the pediatric population
Year: 2025
Type: article
Abstract: PURPOSE: This study provides prospective and retrospective data on safety and performance results with the Bonebridge BCI 602 (MED-EL) active transcutaneous bone conduction implant in children. METHODS: Audiological data were collected at 3 intervals (preoperative, initial activation and 3 months postoperative). Quality of life was assessed with the Speech, Spatial, and Qualities of Hearing (SSQ12/P), KID KINDL and Audio Processor Satisfaction Questionnaire (APSQ) as well as a postoperative questionnaire specifically designed for this study. RESULTS: functional gain (FG) was 31.9 dB HL for the CHL/MHL group and 11.3 dB HL in the SSD patients. CHL/MHL patients had a mean word recognition score (WRS) improvement of 80.6 ± 23.9 % at initial activation and 83 ± 20.3 % at 3 months post-op. Speech recognition in noise at +5 dB SNR in the CHL/MHL group improved from 24.6 ± 28.3 % unaided to 74.9 ± 26 % aided at 3 months post-op. The mean post-op total scores were 5.5 ± 1.8 on the SSQ12/P and 8.87 ± 0.93 on the APSQ questionnaires. No major complications were noted on the postoperative questionnaire; minor complications were resolved by the end of the study. Stable bone and air conduction thresholds confirmed device safety. CONCLUSION: The Bonebridge BCI 602 is safe and effective for use in the pediatric population.
Authors: Laura Cavallé Garrido, Carlos de Paula Vernetta, Abel Guzmán Calvete, Javier Álvarez Arocas, Cláudia Gonçalves, Miguel Armengot Carceller
Language: English
Subfield: Cognitive Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
OpenAlex ID: W4415459698